Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.

Nature reviews. Clinical oncology - 1 Nov 2017

Gan Hui K, van den Bent Martin, Lassman Andrew B, Reardon David A, Scott Andrew M

Abstract excerpt

Glioblastomas are high-grade brain tumours with a poor prognosis and, currently, few available therapeutic options. This lack of effective treatments has been linked to diverse factors, including target selection, tumour heterogeneity and poor penetrance of therapeutic agents through the blood-brain barrier and into tumours. Therapies using monoclonal antibodies, alone or linked to cytotoxic payloads, have proved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood-Brain Barrier
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to ErbB Receptors

Share to EGFR gene

Share to Glioblastoma

Share to Immunoconjugates

Share to Mutation

Source

Identifiers

PMID: 28675164
DOI: 10.1038/nrclinonc.2017.95

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.PMID 28675164Read ↗

Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future DirectionsSemantic proximity Read ↗

Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumorsSemantic proximity Read ↗

Unravelling the Glioblastoma Tumour Microenvironment: Can Aptamer Targeted Delivery Become Successful in Treating Brain Cancers?Semantic proximity Read ↗

The challenges associated with molecular targeted therapies for glioblastoma.Semantic proximity Read ↗

Molecular targeting of glioblastoma: Drug discovery and therapiesSemantic proximity Read ↗

Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.Semantic proximity Read ↗

Next generation neuro-oncology.Semantic proximity Read ↗

Management of glioblastoma: State of the art and future directions.Semantic proximity Read ↗

Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome ResistanceSemantic proximity Read ↗

<i>In Vivo</i> Selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft modelSemantic proximity Read ↗

Toward precision medicine in glioblastoma: the promise and the challenges.Semantic proximity Read ↗

Personalized medicine for glioblastoma: current challenges and future opportunities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.